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Summary
Genome editing with engineered nucleases (GEEN) represents a highly specific and efficient tool
for crop improvement with the potential to rapidly generate useful novel phenotypes/traits.
Genome editing techniques initiate specifically targeted double strand breaks facilitating DNA-
repair pathways that lead to base additions or deletions by non-homologous end joining as well
as targeted gene replacements or transgene insertions involving homology-directed repair
mechanisms. Many of these techniques and the ancillary processes they employ generate
phenotypic variation that is indistinguishable from that obtained through natural means or
conventional mutagenesis; and therefore, they do not readily fit current definitions of genetically
engineered or genetically modified used within most regulatory regimes. Addressing ambiguities
regarding the regulatory status of genome editing techniques is critical to their application for
development of economically useful crop traits. Continued regulatory focus on the process used,
rather than the nature of the novel phenotype developed, results in confusion on the part of
regulators, product developers, and the public alike and creates uncertainty as of the use of
genome engineering tools for crop improvement.
Introduction
Genome editing with engineered nucleases (GEEN) has rapidly
emerged as a leading tool for investigating gene function and for
creating genetic variation using site-directed genomic alterations.
When applied to economically important plant species, GEEN
additionally provides a highly specific and efficient means to
generate useful novel phenotypes. With the advent of genome
editing as a readily accessible technology to the research
community, the question arises as to how plants expressing
unique traits derived by genome editing will be received by the
public at large and treated within various regulatory domains.
This question cannot be easily answered from a process
viewpoint, as site-directed genome editing may range from
mutations involving a single base change to transgene insertions.
Addressing ambiguities regarding the regulatory status of
genome-edited crops is critical to the application of genome
editing for developing economically useful crop traits. In this
review, progress in GEEN and related techniques in higher plants
is considered with respect to the current regulatory status for
genome-edited crops.
Genome editing techniques
The earliest example of genome editing (Table 1) in higher plants
involved oligonucleotide-mediated mutagenesis (OMM) to cause
site-specific gene targeting using chemically synthesized oligonu-
cleotides with base replacement or addition caused by endoge-
nous DNA-repair enzymes (Beetham et al., 1999). The method
differs from GEEN approaches in that OMM does not deliver a
nuclease to the site of action. Optimized OMM trait development
systems are resulting in the first genome-edited crops for
commercial release (Pratt, 2012).
Recent discoveries and advances in genome editing use site-
directed nucleases (SDNs) where engineering of the nuclease
allows for highly specific targeting to any given gene of interest.
The array of SDNs which have been used for genome editing in
higher plants encompasses engineered meganucleases (EMNs
also referred to as LAGLIDADG endonucleases or homing
nucleases), zinc finger nucleases (ZFNs), transcriptional activator-
like effector nucleases (TALENs) and clustered regularly
interspaced short palindromic repeats in conjunction with the
associated Cas9 endonuclease (CRISPR/Cas9) (Gaj et al., 2013;
Osakabe and Osakabe, 2014). These various GEEN methods
operate in a similar fashion to generate a double strand break
(DSB) at a specific location in the genome and are comprised of
engineered proteins consisting of a DNA binding domain to
confer site specificity and an endonuclease domain to cause the
DSB (Curtin et al., 2012). A variety of natural DNA repair
mechanisms involving nonhomologous end joining (NHEJ) or
homologous recombination (HR) can be exploited to allow for
targeted genome modifications in vivo. When NHEJ rejoins DSBs
to repair broken chromosomes, the result is often imprecise,
introducing mutations at the cut site that can alter gene function
and serve as a source of induced genetic variation. Alternatively,
DSB-induced HR can be used for highly specific gene targeting
(homology-directed repair, HDR) involving either gene replace-
ment or gene insertion enabling precise genome modification
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based on the exogenously introduced homologous template
(Osakabe and Osakabe, 2014; Zhang et al., 2013).
Generating a DSB at a specific chromosomal location is the
critical step in site-directed genome engineering. In the case of
EMNs, ZFNs and TALENs, gene targeting is accomplished through
protein-based DNA recognition domains; whereas CRSPRs utilize
a single guide RNA (sgRNA) for directing the accompanying Cas9
nuclease (Curtin et al., 2012; Jones, 2015). The nature and
specificity of GEEN methods vary, which influences both the way
they are used and the ease of use.
Genome editing approaches
Approaches facilitated with recombinant DNA (rDNA)
To modify a plant gene through genome engineering, it is
typically necessary to design and develop the SDN that is delivered
to the plant cells by genetic transformation. In the case of HDR, a
donor molecule must also be introduced. Following induction of
nuclease expression and regeneration of plants, the plant events
must be screened for the desired change. The process involves
two independent loci of interest, the site of insertion for a
transgene encoding the SDN and the target locus to be acted on
by the SDN. These loci are not commonly linked and so the
transgenic elements are readily removed by selection for null
segregant lines in the T1 generation to produce subsequent plant
generations that have been edited but are devoid of the tools
used for the process (Curtin et al., 2012).
The genome editing possibilities facilitated through GEEN may
involve mutagenesis, gene replacement, gene editing, gene
insertion, and site-directed deletions or inversions (Curtin et al.,
2012). The attributes of each in conjunction with the overall
process for insertion, targeting, recovery and removal of trans-
genic elements may represent differing outcomes in terms of the
way they will be assessed by regulators (see, Genome editing
regulatory status and opinion). For instance, site-directed muta-
tions are analogous to natural processes or mutation breeding
with the exception that off-target effects can be greatly limited
through design and selection of highly binding-specific SDNs or
OMMs (Hartung and Schiemann, 2014) as well as by downstream
selection to minimize undesired phenotypes. Additionally, the use
of GEEN to deliver transgenes to a common site not only
improves the efficiency and quality of transformations, but it can
simplify the molecular characterization of events for product
development and regulatory assessments.
Approaches involving other than rDNA
A further novel approach to genome editing is the possibility for
SDN introduction through a means other than insertion of SDN-
encoding genes into nuclear DNA (Kathiria and Eudes, 2014;
Pauwels et al., 2014). Such approaches include direct insertion into
cells of the SDN (Martin-Ortigosa et al., 2014) or of messenger
RNA (mRNA) encoding the SDN (Yamamoto et al., 2009), or the
use of plasmid (Belhaj et al., 2013) or viral vectors (Baltes et al.,
2014; Marton et al., 2010) that do not integrate into the host
genome. Delivering the genome editing machinery in these ways
may circumvent transformation in difficult to transform plant
systems therefore increasing the utility and accessibility of genome
editing. These transient approaches also simplify the process of
developing promising phenotypes, as they avoid regulatory trig-
gers for rDNA techniques by eliminating the introduction of
transgenic elements (see, Genome editing regulatory status and
opinion). To date, approaches such as use of mRNA have been
restricted largely to gene therapy considerations (Tavernier et al.,
2011), so their eventual utility for genome editing of crop plants is
yet to be developed. On the other hand, direct introduction of
protein for gene editing in plants currently shows good promise
(Martin-Ortigosa et al., 2014) as does the possibility for employing
plasmid or viral vectors (Baltes et al., 2014; Belhaj et al., 2013).
Genome editing of economically important
plants
Genome editing is being applied with increasing frequency to
economically important plants to demonstrate proof of concept
in terms of technical feasibility, regulatory acceptance and
commercial viability (Table 2).
Table 1 Genome editing acronyms, terms and definitions (Breyer et al., 2009; Kim and Kim, 2014; Osakabe and Osakabe, 2014; de Souza, 2012)
CRSPR Clustered Regularly-Interspaced Short
Paloindromic Repeats
Programable nucleases comprised of bacterially derived endonuclease (Cas9) and a single-guide RNA (sgRNA)
DSB Double Strand Break Cleavage in both strands of double-stranded DNA where the two strands have not separated
EMN Engineered Mega Nuclease Microbially derived meganucleases that are modified, fused, or rationally designed to cause site-directed DSB.
Also referred to as LAGLIDADG endonucleases or homing nucleases.
GEEN Genome Editing with
Engineered Nucleases
Genetic engineering where DNA is inserted, replaced, or removed from a genome using SDN.
HDR Homology-Directed Repair A mechanism for DSB repair using a DNA sequence homologous to the break site that serves as a template
for homologous recombination.
HR Homologous Recombination A genetic recombination process where two similar DNA strands exchange nucleotide sequences.
NHEJ Non Homologous End Joining A means for repair of DSB without the use of a homologous repair sequence. An error-prone process that
often causes small insertions or deletions at the DSB site resulting in mutations.
OMM Oligonucleotide Mediated
Mutagenesis
Site-specific mutation with chemically-synthesized oligonucleotide with homology to the target site (other than
for the intended nucleotide modification).
SDN Site Directed Nuclease Engineered DNA nucleases that are programmed to specific sites within the genome where they cleave a DNA
chain by separating nucleotides.
TALEN Transcriptional Activator-Like
Effector Nuclease
Programmable nucleases comprised of the DNA binding domain of Xanthomonas-derived TAL effectors fused
with FokI restriction endonuclease.
ZFN Zinc Finger Nuclease Programable nucleases comprised of the DNA binding domain of a zinc-finger protein and the DNA-cleaving
nuclease domain of the FokI restriction endonuclease.
ª 2015 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 14, 510–518
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Early genome editing proof of concept in crop plants was
demonstrated with OMM for expression of herbicide resistance in
maize, rice, tobacco and wheat (Beetham et al., 1999; Dong
et al., 2006; Iida and Terada, 2005; Kochevenko and Willmitzer,
2003; Okuzaki and Toriyama, 2004; Zhu et al., 1999, 2000).
Development is proceeding toward commercialization in 2016 of
Cibus 5715 herbicide tolerant canola (Beetham et al., 2005)
which has been approved for use in Canada (Pratt, 2012),
deemed not subject to regulation by USDA in the United States
(Sparrow et al., 2013) and is planned for release into European
markets despite public questions as to the regulation of this
technology (Harvey, 2014).
The use of an EMN for genome editing of an agronomic crop
was first demonstrated using a native endonuclease modified
through a structure-based protein design method to recognize
and induce highly specific DSBs at a specific locus in maize,
resulting in gene disruption through deletions or insertions of
short base segments by NHEJ (Gao et al., 2010). Recently, an
EMN engineered from a yeast endonuclease, and also optimized
for site recognition through a rational design approach, has been
used to precisely target gene insertions into cotton plants for
delivery of an herbicide tolerance gene at a specific, predefined
site adjacent a previously inserted insect resistance gene (D’Hal-
luin et al., 2013).
A site-specific ZFN employing HDR has been used to disrupt the
IPK1 gene in maize by directed insertion of the PAT gene resulting
in low-phytase maize with herbicide tolerance (Shukla et al.,
2009). Subsequently, a site-specific trait stacking approach using
a ZFN was accomplished in maize by first producing a line
containing an herbicide resistance gene and a linked synthetic
ZFN target site, and then using ZFN-targeted site-specific
integration of a second herbicide resistance gene flanked by the
ZFN target site; thus allowing multiple trait stacking at a specific
locus (Ainley et al., 2013).
In the first instance of TALENs being applied toward crop
improvement, the rice disease susceptibility gene OsSWEET14
was modified by site-directed mutation to insert or delete
nucleotide sequences ranging from 3 to 55 bp (Li et al., 2012).
Subsequent genetic segregation resulted in disease-resistant null
segregant rice lacking the selection marker and TALEN genes.
Further applications of TALEN technology in economically impor-
tant plants have been shown for rice, barley and maize (Char
et al., 2015; Gurushidze et al., 2014; Li et al., 2012; Liang et al.,
2014; Shan et al., 2013; Wendt et al., 2013).
A Cas9-single guide RNA (sgRNA) system, representing a
simplified form of the type II CRISPR/Cas9 system from Strep-
tococcus pyogenes, has been successfully used for genome
editing of both dicot and monocot crop species (Jiang et al.,
2013). Genes encoding Cas9/sgRNA and a nonfunctional
mutant green fluorescence protein (GFP) were delivered by
Agrobacterium tumefaciens to sorghum (as well as to Arabidop-
sis). In a second demonstration of the Cas9-sgRNA system, rice
protoplast cells were transformed with constructs targeting the
promoter region of the OsSWEET14 and OsSWEET11 bacterial
blight susceptibility genes to contain mutated DNA sequences at
the target sites.
Regulatory background
Worldwide, regulators dealing with the assessment of geneti-
cally modified (GM) crops generally support a scientific position
that the plant phenotype arising from the application of a T
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given biotechnology process should be the focus of safety
determinations. In practice, however, due to the governing
statutes in various agencies, nations and regions of the
world, there is a tendency for the process used in genetic
engineering to determine the path to regulatory assessments
and approval.
Canada is unique among nations currently evaluating GM
crops for environmental release because of the strong adherence
to the phenotype (i.e. a product basis) when determining the
regulatory status of a plant expressing a novel trait (Smyth and
McHughen, 2008). Thus, with this emphasis on the product
versus the process, plant novel traits (PNTs) developed from
conventional breeding, mutagenesis, transgenesis or genome
editing will all be subject to a similar regulatory approval process.
Crop phenotypes for herbicide resistance have been developed
from each of the forgoing processes and have been subject to
evaluation and approval by Canadian regulators as PNTs (Cana-
dian Food Inspection Agency, 2015).
The regulatory paradigm followed in the United States under
the coordinated framework distributes authority among the US
Food and Drug Administration (FDA), Environmental Protection
Agency (EPA) and Department of Agriculture (USDA). The
coordinated framework relies on existing statutes for regulatory
authority rather than on a national biosafety law as found
elsewhere throughout the world. Even though the framework is
ostensibly product based, process frequently comes into play for
regulatory assessment of what are termed genetically engineered
(GE) crops in the United States.
The FDA has a long-standing position of considering foods and
feeds derived from rDNA technology as being as safe as their
non-GE counterparts and maintains a strong focus on product-
based considerations. The FDA evaluates safety of GE crops and
their derived foods and feeds through informal consultation
focused on compositional equivalence of the GE product and its
non-GE comparator, especially as it relates to allergens, antinu-
trients and toxins (McHughen and Smyth, 2008). This process is
evolving and a premarket notification procedure was suggested
by FDA in 2001 in response to public pressure for a formal safety
evaluation for GE-derived foods and feeds (http://www.fda.gov/
Food/FoodScienceResearch/Biotechnology/).
The regulation of GE crops at EPA is more directed toward
product through regulatory authority that is limited to traits
developed to intentionally exhibit pesticide activity (McHughen
and Smyth, 2008). Assessment within EPA is intended to regulate
the pesticidal property rather than the crop. Thus, in the case of a
crop expressing a Cry toxin derived from Bacillus thuringiensis,
regulators focus on the plant incorporated pesticide—the
expressed Cry protein—given that the transformed crop other-
wise shows phenotypic similarity to the nontransformed pheno-
type (comparator).
The USDA serves as the lead US regulator under the
coordinated framework and draws its authority to regulate GE
crops to the extent that the derived plant may behave as a plant
pest or noxious weed (McHughen and Smyth, 2008). Through
this approach if elements of a plant pathogen are used in
development of the GE crop, the crop falls within USDA
regulatory purview but in other cases does not. For instance,
plants transformed by Agrobacterium tumefaciens are typically
subject to regulatory review by USDA whereas those trans-
formed by biolistics are not when the gene donor, recipient and
vector are otherwise not known plant pests (Camacho et al.,
2014).
Under European Union legislation, GM crops are specifically
defined as “an organism . . . in which the genetic material has
been altered in a way that does not occur naturally by mating
and/or natural recombination.” Furthermore, techniques involv-
ing recombinant nucleic acid are explicitly cited as subject to
regulation and mutagenesis is explicitly excluded (European
Parliament, 2001). Thus, crops resulting from the process of
genetic modification as defined are subject to special regulatory
consideration, which sets them apart, for instance, from similar
crops generated by mutagenic approaches which are explicitly
excluded from EU regulatory consideration. This special consid-
eration for GM crops adds many years to the development
timelines for crops developed with rDNA techniques and intended
for markets in Europe, and as of now the political process in
Europe has restricted widespread entry of GM crops into
commercial use (Smyth et al., 2014). Recent and pending actions
within the EU to allow for country by country GMO cultivation
and food and feed approvals portend further restriction of
commercialized GM crop use in Europe (European Commission,
2015; European Parliament, 2015).
The EU adheres to a precautionary principle, which enables,
“where scientific data do not permit a complete evaluation of the
risk,. . . to stop distribution or order withdrawal from the market
of products likely to be hazardous” http://europa.eu/legislation_-
summaries/consumers/consumer_safety/l32042_en.htm. The EU
precautionary approach and its unique application to the defined
process of genetic modification is often reflected in emerging
regulatory networks elsewhere in the world where new biosafety
laws are being adopted and implemented (Bayer et al., 2010;
Gupta et al., 2008; Okeno et al., 2013). Elsewhere, countries
such Australia, Argentina and Brazil have successfully adopted
process-based regulatory approaches that may factor social and
economic factors into a regulatory framework, but which achieve
regulatory approvals in a manner relatively consistent with that
seen in North America (Smyth and Phillips, 2014).
Genome editing regulatory status and opinion
The regulation of genome-edited crops has been widely discussed
and reviewed by regulators and the scientific community (Breyer
et al., 2009; European Food Safety Authority Panel on Genetically
Modified Organisms, 2012; Gruere and Rao, 2007; International
Life Sciences Institute, 2013; Lusser and Davies, 2013; Lusser and
Rodrıguez-Cerezo, 2012; Lusser et al., 2011, 2012; Pauwels
et al., 2014; Podevin et al., 2012, 2013). The consensus arising
from these deliberations shows that the degree of regulatory
scrutiny on genome-edited crops will be determined by the
nature of the DNA-repair process used, the characteristics and
intended use of the phenotype that is developed and the existing
regulatory strictures within the geopolitical region of release.
In the EU, failure to embrace transgenic technologies has
hindered product development and caused industry retraction
(Hope, 2013). Therefore, EU regulatory experts and scientists have
been keen to explore GEEN and other new breeding technologies
as a pathway for crop improvement that circumvents the near
impossibility for crops defined as GM to obtain public and
regulatory approval (Breyer et al., 2009; Hartung and Schiemann,
2014; Pauwels et al., 2014; Podevin et al., 2012, 2013). While the
ultimate hope is for a renewed recognition within the EU of the
importance of product over process as a regulatory paradigm
(Hartung and Schiemann, 2014), the more pragmatic goal at this
time is that those aspects of GEEN technology that represent site-
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directedmutationwill not be regulated in the EU or throughout the
world, with the exception of Canada and its PNT regulation
(International Life Sciences Institute, 2013).
Regulatory discussion of a wide range of new breeding
techniques applied to crop development was initiated in 2011
with an EU-convened international workshop that considered the
techniques then available for site-directed genome editing (Lusser
et al., 2011). Based on the categorizations identified by this group,
its elaboration by Podevin et al. (2012)—and accounting for the
emergence of new techniques in the interim—a schema for
regulatory characterization specific to genome editing techniques
can be described (Figure 1). This schema considers the approach to
DSB repairs that are achieved by NHEJ (SDN1), homologous
recombination (SDN2) or transgene insertion (SDN3) and whether
the technique for introduction of the GEEN is transient (Category
1), introduces rDNA within the plant genome with subsequent
removal (Category 2) or entails stable plant genome integration of
rDNA (Category 3). The OMM approach produces DSB repaired by
NHEJ and therefore is analogous to SDN1 in terms of its regulatory
characterization to the extent the changes are viewed as point
mutations and not template insertions (Hartung and Schiemann,
2014; Lusser and Davies, 2013).
Category 1 techniques involve transient introduction of
recombinant DNA using in vitro synthesized nucleic acids and
DNA delivery methods that do not integrate into the host genome
(Pauwels et al., 2014). These techniques, therefore, resemble
transgenic processes but produce phenotypes that are indistin-
guishable from plants obtained through conventional plant
breeding. The techniques would include site-specific point muta-
tions with oligonucleotides (OMM), site-specific random muta-
tions by NHEJ (SDN1) and site-specific mutations with DNA repair
via homologous recombination (SDN2). Novel techniques avoid-
ing the use of rDNA through direct introduction of the nuclease
or mRNA encoding the nuclease (Baltes et al., 2014; Martin-
Ortigosa et al., 2014) to catalyse similar mutation events would
also fall into this category.
Category 2 consists of stable introduction of rDNA into the
host genome and an intermediate step involving expression of
SDN1 or SDN2 to effect DSBs and repairs. Subsequent breeding
selection for null segregants results in phenotypes that are
indistinguishable from phenotypes obtained through conven-
tional plant breeding. Therefore, evidence will generally be
lacking in the product to indicate a transgenic process was
involved in the intermediate step.
Plant phenotypes developed by SDN1 methods as described in
either of the forgoing categories represent simple point mutations
and with few exceptions (Canada) regulators do not consider
crops developed by mutagenesis in the same context as GM
crops. The regulatory opinions regarding plant phenotypes
developed by SDN2 methods are not as clear, as the nature
and extent of the edits used to effect the desired change in the
phenotype obtained by the technique would influence opinions
as to whether the phenotype represented a GM product. For
instance, deletions are viewed as less consequential than are
additions. And in the case of additions, the greater the number of
bases added, the greater the level of regulatory concern.
Important in this context is the determination as to whether the
NHEJ accomplished by the technique is viewed as a template
insertion into the genome (Lusser and Davies, 2013).
Finally, Category 3 involves techniques that result in stable
integration of rDNA where GEEN is used to specifically target
delivery of a transgene or multiple transgenes through insertion
by homologous recombination (SDN3). Current examples of this
technique involve the site-directed stacking of transgenes (D’Hal-
luin et al., 2013); thus, they simply represent a refined technique
to accomplish transgenesis and would be considered no differ-
ently than GM products by regulators. The European Food Safety
Authority (EFSA) Panel on Genetically Modified Organisms—an
expert panel providing independent scientific advice to EFSA on
GMOs—has developed the regulatory opinion that existing EFSA
guidance documents apply to the SDN3 technique (European
Food Safety Authority Panel on Genetically Modified Organisms,
2012). But because the technique can specifically target trans-
gene delivery into the genome, it has the potential to minimize
potential hazards associated with gene disruption or regulatory
elements in the recipient genome. Thus, plants developed using
SDN3 methods may require less data for risk characterization than
more conventional approaches to transgenesis.
Regulatory consideration of these various methodologies is an
ongoing process as regulators throughout the world adhere to a
case-by-case paradigm for decision-making. Therefore, until a
significant body of regulatory decisions emerges, there will be
uncertainty as to the regulatory classification of plants developed
by GEEN and related techniques. The general scientific sentiment
of regulators to date is that gene-edited crops are not uniformly
subject to the same regulatory standards as transgenic crops
(Lusser et al., 2011), but some green and NGO groups as well as
governance experts are beginning to argue otherwise over
Category 1
Transient expression 
resulting in
site-specific DSB and 
repair
Category 2
Stable genomic introduction 
of rDNA with intermediate 
steps to generate 
transgene-free null 
segregants
Category 3
Stable genomic 
integration of
recombinant DNA
SDN1*
Site-directed random 
mutation involving NHEJ
Low 
• Low for deletions
• Case-by-case for addition
• Higher as size of insertion 
increases
N/A 
SDN2
site-directed homologous 
repair involving one or 
very few nucleotides
Case-by-case Case-by-case N/A
SDN3
site-directed transgene 
insertion
N/A N/A
High, moderated for well
characterized insertion 
sites
Method
Category
Figure 1 Relationship of site-directed genome
approach to the anticipated degree of regulatory
scrutiny of the plant phenotype obtained.
*Current uses of OMM are analogous to SDN1 in
terms of regulatory scrutiny.
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concerns that these new technologies not escape regulatory
scrutiny (Camacho et al., 2014; Harvey, 2014). Ultimately, the
regulatory approach taken toward plants developed using GEEN
techniques will be constrained by the interpretation of language
in existing national, regional and international statutes governing
GM crops.
Within the United States, the USDA has provided guidance to
product developers as to the regulatory status of products of
modern biotechnology through responses to formal letters of
inquiry submitted to the agency. These responses have broad
relevance to FDA and EPA as well through the US coordinated
framework. The guidance to date (Table 3) suggests that site-
directed approaches that result in targeted deletions of endoge-
nous nucleotides (SDN1) would not be regulated articles under
USDA statutes, nor would approaches initiated with transgenesis
that in intermediary steps selected for the absence of the
transgenic elements (null segregants); however, for site-directed
methods involving targeted oligonucleotide insertions or substi-
tutions, further case-specific determinations would be required
(Camacho et al., 2014).
Public understanding of genome editing and
regulatory implications
The plant research and development community is moving
toward a number of new breeding technologies that represent
options for increased innovation and which may find greater
public and regulatory acceptance over the use of transgenic
approaches. In addition to genome editing as discussed here,
these new breeding technologies include, cisgenesis, intragenesis
and grafting to GM rootstock, as well as some instances of RNA
interference (Tait and Barker, 2011). The determination of the
specific technology that should be employed in a given instance
of crop improvement will depend not only on the best approach
scientifically and technically, but the most viable approach in
terms of public understanding and the regulatory pathway for
approval (Chapotin and Wolt, 2007). The US regulatory frame-
work is presently challenged in its ability to appropriately weigh
and analyse novel breeding approaches, while over-regulating
transgenic technologies with a clear record of safety (Camacho
et al., 2014). This limitation effects both the product developer’s
need for greater certainty in the regulatory process and the
public’s desire for appropriate governance of new technologies.
Early considerations of the regulation of GEEN and related
technologies cite governance approaches and stakeholder
involvement as seen in Europe as preferable to approaches in
the US (Kuzma and Kokotovich, 2011); but this is of course an
incomplete answer given the inability of the EU to make progress
in the adoption of GM crops in general and the slowing pace in
adopting regulatory positions on genome editing despite early
leadership in the area. From 2007 through 2011, >35% of
genome editing publications emanated from Europe but research
progress is being rapidly outpaced by efforts in the United States
(Kuzhabekova and Kuzma, 2014), perhaps because of a greater
openness in the United States to technology innovation (Pew
Research Center, 2015).
The general public’s view of foods derived from products of
modern biotechnology is perhaps the greatest hurdle faced for
definition and implementation of regulatory processes that are
consistent with scientific understanding of new plant breeding
technologies including genome editing. A recent survey conducted
comparing scientist and citizen views on a range of science,
engineering and technology issues showed remarkable differences
in understanding of issues from a scientific and public perspective
(Pew Research Center, 2015). The most pronounced difference
was on the question of safety of genetic engineering where 37%
of the public at large responded that GM foods are generally safe
to eat, whereas 88% of scientists interviewed recognized GM
foods as generally safe. Given this large discrepancy and the
difficulty in conveying concepts of modern biotechnology to the
general public, there is considerable potential that the public may
not immediately embrace genome editing. And in fact some
experts argue that as an emerging technology genome editing
should require greater scrutiny than well-established technologies
such as transgenics (Araki and Ishii, 2015; Camacho et al., 2014).
Public questioning and precautionary mindsets feed the increas-
ingly outsized influence of civil society campaigns in creating
uncertainty as to the safety of GM foods. This influence ripples
worldwide (Paarlberg, 2014) and, therefore, may outpace the
ability of scientists to communicate the opportunities afforded by
genome editing for crop improvement.
Needs within the regulated community
The need to rapidly innovate to introduce novel traits in crops is
heightened by increased world food demand and increasing use
of crops as sources of renewable energy (Edgerton, 2009). The
opportunity for transgenic crop innovation is limited by regulatory
hurdles and continued public unease (Pew Research Center,
2015; Smyth et al., 2014). Transgenic technologies continue to
elicit considerable public misunderstanding and mistrust despite
19 years of commercial use and over 181.5 million hectares in
production globally in 2014 (James, 2014). Largely in response to
effective pressure on the part of a broad spectrum of NGO and
activist groups (Paarlberg, 2014) and the continuing public
pressure it has engendered, the regulatory processes for trans-
genic GE crops (the so-called GMOs) are largely broken in many
parts of the world. Implementation of national biosafety laws is
encumbered in the developing world (Bayer et al., 2010; Okeno
et al., 2013) and long delays in cultivation approvals are reducing
the value of innovation in many regulatory domains (Smyth et al.,
2014). New breeding technologies, especially site-directed
genome editing, are viable alternatives to transgenic crop
production that provide new opportunities for innovation and
which in many cases clearly involve a reduced degree of
regulatory oversight.
Success in advancing GEEN and related technologies for crop
improvement will be limited if public views and regulatory
response continues to be captured within the overriding theme
of GMOs. The continued reliance on process-based definitions
as a guide to regulatory oversight—and the adoption of
process-focused language in public discourse—detracts from
appropriately gauged approaches toward the regulation of
genome-edited crops. Thus, the focus on the nature of the
novel plant phenotype/trait is lost as the appropriate paradigm
for the safety assessment, which encumbers regulatory
approvals for crops derived from both established and emerging
plant breeding techniques. Lacking a fuller emphasis on this
point means that the public may largely misunderstand genome
editing and regulators will be faced with pressure to evaluate
these products within existing biosafety frameworks. Fortu-
nately, progress is being made by regulators in shaping sensible
and pragmatic approaches toward the application of genome
editing for crop improvement but at some point new product-
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based paradigms for regulation of new breeding technologies
must emerge.
Acknowledgement
Partial support for this work comes from the Iowa State University
Crop Bioengineering Consortium. The authors have no conflict of
interest to declare.
References
Ainley, W.M., Sastry-Dent, L., Welter, M.E., Murray, M.G., Zeitler, B., Amora,
R., Corbin, D.R., Miles, R.R., Arnold, N.L. and Strange, T.L. (2013) Trait
stacking via targeted genome editing. Plant Biotechnol. J. 11, 1126–1134.
Araki, M. and Ishii, T. (2015) Towards social acceptance of plant breeding by
genome editing. Trends Plant Sci. 20, 145–149.
Beetham, P.R., Avissar, P.L., Metz, R.A. and Walker, K.A. (2005) Non-transgenic
herbicide resistant plants. US Patent App. 11/051,955.
Baltes, N.J., Gil-Humanes, J., Cermak, T., Atkins, P.A. and Voytas, D.F. (2014)
DNA replicons for plant genome engineering. The Plant Cell, 26, 151–163.
Bayer, J.C., Norton, G.W. and Falck-Zepeda, J.B. (2010) Cost of compliance
with biotechnology regulation in the Philippines: Implications for developing
countries. AgBioForum, 13, 53–62.
Beetham, P.R., Kipp, P.B., Sawycky, X.L., Arntzen, C.J. and May, G.D. (1999) A
tool for functional plant genomics: Chimeric RNA/DNA oligonucleotides cause
in vivo gene-specific mutations. Proc. Nat. Acad. Sci. USA, 96, 8774–8778.
Belhaj, K., Chaparro-Garcia, A., Kamoun, S. and Nekrasov, V. (2013) Plant
genome editing made easy: targeted mutagenesis in model and crop plants
using the CRISPR/Cas system. Plant Methods, 9, 39.
Breyer, D., Herman, P., Brandenburger, A., Gheysen, G., Remaut, E.,
Soumillion, P., Van Doorsselaere, J., Custers, R., Pauwels, K. and Sneyers,
M. (2009) Commentary: genetic modification through oligonucleotide-
mediated mutagenesis. A GMO regulatory challenge? Environ. Biosafety
Res. 8, 57–64.
Camacho, A., Van Deynze, A., Chi-Ham, C. and Bennett, A.B. (2014)
Genetically engineered crops that fly under the US regulatory radar. Nat.
Biotechnol. 32, 1087–1091.
Canadian Food Inspection Agency (2015) Plants Evaluated for Environmental
and Livestock Feed Safety. http://www.inspection.gc.ca/active/scripts/data
base/pntvcn_submitdb.asp?lang=e&crops=15&company=31&trait=enzym&
events=all
Chapotin, S.M. and Wolt, J.D. (2007) Genetically modified crops for the
bioeconomy: meeting public and regulatory expectations. Transgenic Res. 16,
675–688.
Char, S.N., Unger-Wallace, E., Frame, B., Briggs, S.A., Main, M., Spalding,
M.H., Vollbrecht, E., Wang, K. and Yang, B. (2015) Heritable site-specific
mutagenesis using TALENs in maize. Plant Biotechnol. J., pp. 1–9.
doi:10.1111/pbi.12344.
Curtin, S.J., Voytas, D.F. and Stupar, R.M. (2012) Genome engineering of crops
with designer nucleases. The Plant Genome, 5, 42–50.
D’Halluin, K., Vanderstraeten, C., Van Hulle, J., Rosolowska, J., Van Den
Brande, I., Pennewaert, A., D’Hont, K., Bossut, M., Jantz, D., Ruiter, R. and
Broadhvest, J. (2013) Targeted molecular trait stacking in cotton through
targeted double-strand break induction. Plant Biotechnol. J. 11, 933–941.
Dong, C., Beetham, P., Vincent, K. and Sharp, P. (2006) Oligonucleotide-
directed gene repair in wheat using a transient plasmid gene repair assay
system. Plant Cell Rep. 25, 457–465.
Edgerton, M.D. (2009) Increasing crop productivity to meet global needs for
feed, food, and fuel. Plant Physiol. 149, 7–13.
European Commission (2015) Proposal for a regualtion of the European
Parliament and of the Council amending Regulation (EC) No 1829/2003 as
regards the possibility for the Member States to restrict or prohibit the use of
genetically modified food and feed on their territory. Brussels.
European Food Safety Authority Panel on Genetically Modified Organisms.
(2012) Scientific opinion addressing the safety assessment of plants
developed using zinc finger nuclease 3 and other site-directed nucleases
with similar function. EFSA J. 10, 2943.
European Parliament (2015) Directive (EU) 2015/412 of the European
Parliament and of the Council of 11 March 2015 amending Directive 2001/
18/EC as regards the possibility for the Member States to restrict or prohibit
the cultivation of genetically modified organisms (GMOs) in their territory
Text with EEA relevance. Off. J. Eur. Union L 68/1.
Gaj, T., Gersbach, C.A. and Barbas, C.F. (2013) ZFN, TALEN, and CRISPR/
Cas-based methods for genome engineering. Trends Biotechnol. 31,
397–405.
Gao, H., Smith, J., Yang, M., Jones, S., Djukanovic, V., Nicholson, M.G., West,
A., Bidney, D., Falco, S.C. and Jantz, D. (2010) Heritable targeted
mutagenesis in maize using a designed endonuclease. Plant J. 61, 176–187.
Gruere,G.P. andRao,S. (2007)A reviewof international labelingpoliciesofgenetically
modified food to evaluate India’s proposed rule. AgBioForum, 10, 51–64.
Gupta, K., Karihaloo, J. and Khetarpal, R. (2008) Biosafety Regulations of Asia-
Pacific Countries. pp. 108. Bangkok: Asia-Pacific Association of Agricultural
Research Institutions; Asia-Pacific Consortium on Agricultural Biotechnology,
New Delhi and Food and Agricultural Organization of the United Nations,
Rome.
Gurushidze, M., Hensel, G., Hiekel, S., Schedel, S., Valkov, V. and Kumlehn, J.
(2014) True-breeding targeted gene knock-out in barley using designer TALE-
nuclease in haploid cells. PLoS ONE, 9, e92046.
Hartung, F. and Schiemann, J. (2014) Precise plant breeding using new genome
editing techniques: opportunities, safety and regulation in the EU. Plant J. 78,
742–752.
Harvey, F. (2014, July 21) Genome editing of crops may be restricted by EU
rules, warn scientists. In The Guardian, Retrieved from http://www.
theguardian.com/environment/2014/jul/21/genome-editing-crops-restricted-
eu-rules-scientists-warn.
Hope, C. (2013, July 18) Major GM food company Monsanto ‘pulls out of
Europe’. In Telegraph, Retrieved from http://www.telegraph.co.uk/news/
earth/environment/10186932/Major-GM-food-company-Monsanto-pulls-
out-of-Europe.html.
Iida, S. and Terada, R. (2005) Modification of endogenous natural genes
by gene targeting in rice and other higher plants. Plant Mol. Biol. 59,
205–219.
International Life Sciences Institute (2013) ILSI Workshop on New Breeding
Technologies (NBT). Canaberra: International Life Sciences Institute SEA
Region Australasia.
James, C. (2014) Global Status of Commercialized Biotech/GM Crops: 2014.
ISAAA Brief No. 49. Ithaca, NY: ISAAA.
Jiang, W., Zhou, H., Bi, H., Fromm, M., Yang, B. and Weeks, D.P. (2013)
Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification
in Arabidopsis, tobacco, sorghum and rice. Nucleic Acids Res. 41, e188.
doi:10.1093/nar/gkt780.
Jones, H.D. (2015) Regulatory uncertainty over genome editing. Nat. Plants, 1,
1–3.
Kathiria, P. and Eudes, F. (2014) Nucleases for genome editing in crops.
Biocatal. Agric. Biotechnol. 3, 14–19.
Kim, H. and Kim, J.-S. (2014) A guide to genome engineering with
programmable nucleases. Nat. Rev. Genet. 15, 321–334.
Kochevenko, A. and Willmitzer, L. (2003) Chimeric RNA/DNA oligonucleotide-
based site-specific modification of the tobacco acetolactate syntase gene.
Plant Physiol. 132, 174–184.
Kuzhabekova, A. and Kuzma, J. (2014) Mapping the emerging field of genome
editing. Technol. Anal. Strateg. 26, 321–352.
Kuzma, J. and Kokotovich, A. (2011) Renegotiating GM crop regulation. EMBO
Rep. 12, 883–888.
Li, T., Liu, B., Spalding, M.H., Weeks, D.P. and Yang, B. (2012) High-efficiency
TALEN-based gene editing produces disease-resistant rice. Nat. Biotechnol.
30, 390–392.
Liang, Z., Zhang, K., Chen, K. and Gao, C. (2014) Targeted mutagenesis in Zea
mays using TALENs and the CRISPR/Cas system. J. Genetics Genomics, 41,
63–68.
Lusser, M. and Davies, H.V. (2013) Comparative regulatory approaches for
groups of new plant breeding techniques. New Biotechnol. 30, 437–446.
Lusser, M. and Rodrıguez-Cerezo, E. (2012) Comparative regulatory approaches
for new plant breeding techniques. In Workshop proceedings. European
Commission. JRC Technical Report EUR.
ª 2015 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 14, 510–518
The Regulatory Status of Genome-edited Crops 517
Lusser, M., Parisi, C., Plan, D. and Rodriguez-Cerezo, E. (2011) New plant
breeding techniques: state-of-the-art and prospects for commercial
development. In Report EUR 24760, (Technical, J.R.C., ed), pp. 1–39.
Brussels, Belgium: European Commission Joint Research Centre.
Lusser, M., Parisi, C., Plan, D. and Rodrıguez-Cerezo, E. (2012) Deployment of
new biotechnologies in plant breeding. Nat. Biotechnol. 30, 231–239.
Martin-Ortigosa, S., Peterson, D.J., Valenstein, J.S., Lin, V.S.-Y., Trewyn, B.G.,
Lyznik, L.A. and Wang, K. (2014) Mesoporous silica nanoparticle-mediated
intracellular Cre protein delivery for maize genome editing via loxP site
excision. Plant Physiol. 164, 537–547.
Marton, I., Zuker, A., Shklarman, E., Zeevi, V., Tovkach, A., Roffe, S., Ovadis,
M., Tzfira, T. and Vainstein, A. (2010) Nontransgenic genome modification in
plant cells. Plant Physiol. 154, 1079–1087.
McHughen, A. and Smyth, S. (2008) US regulatory system for genetically
modified [genetically modified organism (GMO), rDNA or transgenic] crop
cultivars. Plant Biotechnol. J. 6, 2–12.
Okeno, J.A., Wolt, J.D., Misra, M.K. and Rodriguez, L. (2013) Africa’s inevitable
walk to genetically modified (GM) crops: opportunities and challenges for
commercialization. New Biotechnol. 30, 124–130.
Okuzaki, A. and Toriyama, K. (2004) Chimeric RNA/DNA oligonucleotide-
directed gene targeting in rice. Plant Cell Rep. 22, 509–512.
Osakabe, Y. and Osakabe, K. (2014) Genome editing with engineered
nucleases in plants. Plant Cell Physiol. 56, 389–400.
Paarlberg, R. (2014) A dubious success: the NGO campaign against GMOs. GM
Crops Food, 5, 223–228.
Parliament, E. (2001) Directive 2001/18/EC of the European Parliament and of
the Council of 12 March 2001 on the deliberate release into the environment
of genetically modified organisms and repealing Council Directive 90/220/
EEC. Off. J. Eur. Comm. L, 106, 1–38.
Pauwels, K., Podevin, N., Breyer, D., Carroll, D. and Herman, P. (2014)
Engineering nucleases for gene targeting: safety and regulatory
considerations. New Biotechnol. 31, 18–27.
Pew Research Center (2015) Public and Scientists’ Views on Science and
Society. Washington DC: Pew Research Center.
Podevin, N., Devos, Y., Davies, H.V. and Nielsen, K.M. (2012) Transgenic or
not? No simple answer!. EMBO Rep. 13, 1057–1061.
Podevin, N., Davies, H.V., Hartung, F., Nogue, F. and Casacuberta, J.M. (2013)
Site-directed nucleases: a paradigm shift in predictable, knowledge-based
plant breeding. Trends Biotechnol. 31, 375–383.
Pratt, S. (2012, March 28), Growers see new HT canola in 2016. The Western
Producer. Retrieved from http://www.producer.com/2014/03/growers-to-
see-new-ht-canola-in-2016/.
Shan, Q., Wang, Y., Chen, K., Liang, Z., Li, J., Zhang, Y., Zhang, K., Liu, J.,
Voytas, D.F. and Zheng, X. (2013) Rapid and efficient gene modification in
rice and Brachypodium using TALENs. Mol. Plant, 6, 1365–1368.
Shukla, V.K., Doyon, Y., Miller, J.C., DeKelver, R.C., Moehle, E.A., Worden,
S.E., Mitchell, J.C., Arnold, N.L., Gopalan, S. and Meng, X. (2009) Precise
genome modification in the crop species Zea mays using zinc-finger
nucleases. Nature, 459, 437–441.
Smyth, S. and McHughen, A. (2008) Regulating innovative crop technologies in
Canada: the case of regulating genetically modified crops. Plant Biotechnol. J.
6, 213–225.
Smyth, S.J. and Phillips, P.W. (2014) Risk, regulation and biotechnology: the
case of GM crops. GM Crops Food, 5, 170–177.
Smyth, S.J., McDonald, J. and Falck-Zepeda, J. (2014) Investment, regulation,
and uncertainty: managing new plant breeding techniques. GM Crops Food,
5, 44–57.
de Souza, N. (2012) Primer: genome editing with engineered nucleases. Nat.
Methods, 9, 27–27.
Sparrow, P., Broer, I., E Hood, E., Eversole, K., Hartung, F. and Schiemann, J.
(2013) Risk assessment and regulation of molecular farming-a comparison
between Europe and US. Curr. Pharm. Des. 19, 5513–5530.
Tait, J. and Barker, G. (2011) Global food security and the governance of
modern biotechnologies. EMBO Rep. 12, 763–768.
Tavernier, G., Andries, O., Demeester, J., Sanders, N.N., De Smedt, S.C. and
Rejman, J. (2011) mRNA as gene therapeutic: how to control protein
expression. J. Controlled Release, 150, 238–247.
Wendt, T., Holm, P.B., Starker, C.G., Christian, M., Voytas, D.F., Brinch-
Pedersen, H. and Holme, I.B. (2013) TAL effector nucleases induce mutations
at a pre-selected location in the genome of primary barley transformants.
Plant Mol. Biol. 83, 279–285.
Yamamoto, A., Kormann, M., Rosenecker, J. and Rudolph, C. (2009) Current
prospects for mRNA gene delivery. Eur. J. Pharm. Biopharm. 71,
484–489.
Zhang, Y., Zhang, F., Li, X., Baller, J.A., Qi, Y., Starker, C.G., Bogdanove, A.J.
and Voytas, D.F. (2013) Transcription activator-like effector nucleases enable
efficient plant genome engineering. Plant Physiol. 161, 20–27.
Zhu, T., Peterson, D.J., Tagliani, L., St. Clair, G., Baszczynski, C.L. and Bowen, B.
(1999) Targeted manipulation of maize genes in vivo using chimeric RNA/
DNA oligonucleotides. Proc. Nat. Acad. Sci. USA, 96, 8768–8773.
Zhu, T., Mettenburg, K., Peterson, D.J., Tagliani, L. and Baszczynski, C.L. (2000)
Engineering herbicide-resistant maize using chimeric RNA/DNA
oligonucleotides. Nat. Biotechnol. 18, 555–558.
ª 2015 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 14, 510–518
Jeffrey D. Wolt et al.518
